April 17, 2026

Retinal Imaging Model Aids CAD Detection

Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort

Conexiant

April 15, 2026

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Conexiant

April 13, 2026

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Conexiant

April 07, 2026

Maternal Diabetes and the Hidden Risk of ROP

Retrospective cohort study links maternal diabetes to increased ROP risk in premature infants

The Ophthalmologist

April 07, 2026

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Conexiant

March 31, 2026

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

Conexiant

June 01, 2014

Indications and Considerations For Chromodissection

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

September 01, 2016

Innovation in Retina

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

October 01, 2016

CODING Q&A

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician